Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

67.22 -0.58 (-0.86%)
Streaming Delayed Price Updated: 10:10 AM EDT, May 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2
...
24 25 26 27 28 29 30 31 Next >
Why Fate Therapeutics Stock Is Sliding Today
The positive results the company announced after the bell yesterday didn't meet some lofty expectations. 
Via The Motley Fool
The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16) Bio-Rad Laboratories, Inc... 
Via Benzinga
Why NRx Pharmaceuticals Stock Jumped 11.8% Today
The company provided a positive update from a clinical study evaluating its COVID-19 therapy Zyesami. 
Via The Motley Fool
Exposures COVID-19
China's Red Ribbon School Provides a Refuge for Children Living With HIV
China's Red Ribbon School Provides a Refuge for Children Living With HIV 
Via News Direct
Topics Bonds Product Recall
Exposures Debt Markets Legal Product Safety
Wall Street Journal Creates A Pitch In Favor Of Royalty Pharma
Drug development, both a lucrative and a risky segment. Royalty Pharma plc (NASDAQ: RPRX) offers a middle ground for its investors. The Company was founded in 1996 and... 
Via Benzinga
Large Cap Biopharma Stocks provide Growth and Value
The S&P 500 Healthcare Index was up 0.53% and biotech still lags in healthcare yet Large Cap Biopharma is doing well YTD. 
Via Talk Markets
Topics Stocks
Exposures US Equities
What To Know About Rand Paul Failing To Disclose Gilead Stock Purchase For 16 Months
Stock transactions by members of the U.S. Congress and their spouses have been a hot topic over the last several years. A transaction disclosed late Wednesday is drawing heavy... 
Via Benzinga
Analyzing Gilead Sciences's Unusual Options Activity
On Wednesday, shares of Gilead Sciences (NASDAQ:GILD) saw... 
Via Benzinga
Analyzing Gilead Sciences's Unusual Options Activity
Gilead Sciences (NASDAQ:GILD) shares experienced unusual o... 
Via Benzinga
Stocks That Hit 52-Week Highs On Tuesday
Before 10 a.m. ET on Tuesday, 55 companies set new 52-week highs. Points of Interest: Apple (NASDAQ:AAPL) was the largest company by market cap to set a new 52-week... 
Via Benzinga
Gilead Sciences Endows Its Foundation With More Than $200 Million to Support Health Justice, Community Giving and Employee Match Program
Gilead Sciences Endows Its Foundation With More Than $200 Million to Support Health Justice, Community Giving and Employee Match Program 
Via News Direct
Exposures COVID-19
Stocks That Hit 52-Week Highs On Monday
Before 10 a.m. ET on Monday, 71 companies hit new 52-week highs. Highlights: Apple (NASDAQ:AAPL) was the largest firm on a market cap basis to set a new 52-week... 
Via Benzinga
The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12) Adagio Therapeutics, Inc. (... 
Via Benzinga
Exposures Product Safety
10 Health Care Stocks Showing Unusual Options Activity In Today's Session
This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges... 
Via Benzinga
Fake Versions Of Gilead's HIV Drugs Are In Circulation In US
Gilead Sciences Inc (NASDAQ: GILD) warned Thursday that its original HIV treatments Biktarvy and Descovy had been replaced by fake versions at some pharmacies.... 
Via Benzinga
3 Biotech Stocks That Could Make You Richer in August (and Beyond)
All three have blockbuster products already on the market. 
Via The Motley Fool
This High-Risk, High-Reward Biotech Could Make COVID Less Deadly -- and Make Investors Money
An effective oral antiviral therapy for the coronavirus may be around the corner. 
Via The Motley Fool
Exposures COVID-19
International AIDS Society Leaders on the Future of HIV Prevention and Treatment
International AIDS Society Leaders on the Future of HIV Prevention and Treatment 
Via News Direct
Exposures COVID-19
Why Investors Should Like BioNTech's Latest Deal With Gilead
There are several pluses for BioNTech in the deal. 
Via The Motley Fool
Topics Cannabis
Exposures COVID-19 Cannabis
Gilead Sciences (GILD) Q2 2021 Earnings Call Transcript
GILD earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
Gilead Sciences Exceeds Expectations As Remdesivir Success Cushions Slump In HIV Franchise
Gilead Sciences Inc (NASDAQ: GILD) reported Q2 sales of $6.2 billion +21% Y/Y, beating the consensus estimate of $6.07 billion, helped by solid demand for COVID-19... 
Via Benzinga
Amazon Earnings Could Take the Market Down with it
While we've seen sell-offs occur on recent positive earnings surprises, few have been dramatic and none has been as consequential as AMZN could be tomorrow. 
Via Talk Markets
Recap: Gilead Sciences Q2 Earnings
Shares of Gilead Sciences (NASDAQ:GILD) decreased 0.8% in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 68.47% year... 
Via Benzinga
Gilead Earnings Top Views; Biotech Giant Narrows Guidance
Gilead earnings modestly beat Q2 views with the biotech giant narrowing its full-year EPS target range. Gilead dipped late. 
Via Investor's Business Daily
Eli Lilly-Incyte's Rheumatoid Arthritis Drug Gets OK From FDA For Solo Use In Hospitalized COVID-19 Patients
The FDA extended the Emergency Use Authorization (EUA) for Eli Lilly And Co's (NYSE: LLY) and Incyte Corporation's (NASDAQ: INCY) rheumatoid... 
Via Benzinga
Exposures COVID-19 Product Safety
The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
Prioritizing the Needs of the Black LGBTQ+ Community in an Innovative HIV Trial
Prioritizing the Needs of the Black LGBTQ+ Community in an Innovative HIV Trial 
Via News Direct
< Previous 1 2
...
24 25 26 27 28 29 30 31 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.